Literature DB >> 21724467

Myotonic dystrophy mouse models: towards rational therapy development.

Mário Gomes-Pereira1, Thomas A Cooper, Geneviève Gourdon.   

Abstract

DNA repeat expansions can result in the production of toxic RNA. RNA toxicity has been best characterised in the context of myotonic dystrophy. Nearly 20 mouse models have contributed significant and complementary insights into specific aspects of this novel disease mechanism. These models provide a unique resource to test pharmacological, anti-sense, and gene-therapy therapeutic strategies that target specific events of the pathobiological cascade. Further proof-of-principle concept studies and preclinical experiments require critical and thorough analysis of the multiple myotonic dystrophy transgenic lines available. This review provides in-depth assessment of the molecular and phenotypic features of these models and their contribution towards the dissection of disease mechanisms, and compares them with the human condition. More importantly, it provides critical assessment of their suitability and limitations for preclinical testing of emerging therapeutic strategies.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21724467      PMCID: PMC3881009          DOI: 10.1016/j.molmed.2011.05.004

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  98 in total

1.  Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy.

Authors:  Susan A M Mulders; Walther J A A van den Broek; Thurman M Wheeler; Huib J E Croes; Petra van Kuik-Romeijn; Sjef J de Kimpe; Denis Furling; Gerard J Platenburg; Geneviève Gourdon; Charles A Thornton; Bé Wieringa; Derick G Wansink
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

2.  Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2.

Authors:  Y G Weber; R Roebling; J Kassubek; S Hoffmann; A Rosenbohm; M Wolf; P Steinbach; K Jurkat-Rott; H Walter; S N Reske; F Lehmann-Horn; F M Mottaghy; H Lerche
Journal:  Neurology       Date:  2010-03-10       Impact factor: 9.910

3.  PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1.

Authors:  Guey-Shin Wang; Muge N Kuyumcu-Martinez; Satyam Sarma; Nitin Mathur; Xander H T Wehrens; Thomas A Cooper
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

4.  Variant CCG and GGC repeats within the CTG expansion dramatically modify mutational dynamics and likely contribute toward unusual symptoms in some myotonic dystrophy type 1 patients.

Authors:  Claudia Braida; Rhoda K A Stefanatos; Berit Adam; Navdeep Mahajan; Hubert J M Smeets; Florence Niel; Cyril Goizet; Benoit Arveiler; Michel Koenig; Clotilde Lagier-Tourenne; Jean-Louis Mandel; Catharina G Faber; Christine E M de Die-Smulders; Frank Spaans; Darren G Monckton
Journal:  Hum Mol Genet       Date:  2010-01-15       Impact factor: 6.150

5.  Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1.

Authors:  Misha Koshelev; Satyam Sarma; Roger E Price; Xander H T Wehrens; Thomas A Cooper
Journal:  Hum Mol Genet       Date:  2010-01-05       Impact factor: 6.150

6.  Muscleblind1, but not Dmpk or Six5, contributes to a complex phenotype of muscular and motivational deficits in mouse models of myotonic dystrophy.

Authors:  Anna Matynia; Carina Hoi Ng; Warunee Dansithong; Andy Chiang; Alcino J Silva; Sita Reddy
Journal:  PLoS One       Date:  2010-03-25       Impact factor: 3.240

7.  Altered RNA splicing contributes to skeletal muscle pathology in Kennedy disease knock-in mice.

Authors:  Zhigang Yu; Adrienne M Wang; Diane M Robins; Andrew P Lieberman
Journal:  Dis Model Mech       Date:  2009-08-19       Impact factor: 5.758

8.  Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy.

Authors:  Hongqing Du; Melissa S Cline; Robert J Osborne; Daniel L Tuttle; Tyson A Clark; John Paul Donohue; Megan P Hall; Lily Shiue; Maurice S Swanson; Charles A Thornton; Manuel Ares
Journal:  Nat Struct Mol Biol       Date:  2010-01-24       Impact factor: 15.369

9.  Absence of a differentiation defect in muscle satellite cells from DM2 patients.

Authors:  Richard Pelletier; Frederic Hamel; Daniel Beaulieu; Lysanne Patry; Caroline Haineault; Mark Tarnopolsky; Benedikt Schoser; Jack Puymirat
Journal:  Neurobiol Dis       Date:  2009-07-24       Impact factor: 5.996

10.  Pentamidine reverses the splicing defects associated with myotonic dystrophy.

Authors:  M Bryan Warf; Masayuki Nakamori; Catherine M Matthys; Charles A Thornton; J Andrew Berglund
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-12       Impact factor: 11.205

View more
  39 in total

Review 1.  Animal models of muscular dystrophy.

Authors:  Rainer Ng; Glen B Banks; John K Hall; Lindsey A Muir; Julian N Ramos; Jacqueline Wicki; Guy L Odom; Patryk Konieczny; Jane Seto; Joel R Chamberlain; Jeffrey S Chamberlain
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

2.  Most expression and splicing changes in myotonic dystrophy type 1 and type 2 skeletal muscle are shared with other muscular dystrophies.

Authors:  Linda L Bachinski; Keith A Baggerly; Valerie L Neubauer; Tamara J Nixon; Olayinka Raheem; Mario Sirito; Anna K Unruh; Jiexin Zhang; Lalitha Nagarajan; Lubov T Timchenko; Guillaume Bassez; Bruno Eymard; Josep Gamez; Tetsuo Ashizawa; Jerry R Mendell; Bjarne Udd; Ralf Krahe
Journal:  Neuromuscul Disord       Date:  2013-11-15       Impact factor: 4.296

3.  Genome modification leads to phenotype reversal in human myotonic dystrophy type 1 induced pluripotent stem cell-derived neural stem cells.

Authors:  Guangbin Xia; Yuanzheng Gao; Shouguang Jin; S H Subramony; Naohiro Terada; Laura P W Ranum; Maurice S Swanson; Tetsuo Ashizawa
Journal:  Stem Cells       Date:  2015-06       Impact factor: 6.277

4.  Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy.

Authors:  Darren R Bisset; Ewa A Stepniak-Konieczna; Maja Zavaljevski; Jessica Wei; Gregory T Carter; Michael D Weiss; Joel R Chamberlain
Journal:  Hum Mol Genet       Date:  2015-06-16       Impact factor: 6.150

5.  Age-dependent chloride channel expression in skeletal muscle fibres of normal and HSA(LR) myotonic mice.

Authors:  Marino DiFranco; Carl Yu; Marbella Quiñonez; Julio L Vergara
Journal:  J Physiol       Date:  2012-12-17       Impact factor: 5.182

6.  A novel CUG(exp)·MBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1.

Authors:  Amin Haghighat Jahromi; Lien Nguyen; Yuan Fu; Kali A Miller; Anne M Baranger; Steven C Zimmerman
Journal:  ACS Chem Biol       Date:  2013-03-20       Impact factor: 5.100

7.  Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy.

Authors:  Yongping Yue; Ibrahim M Binalsheikh; Stacey B Leach; Timothy L Domeier; Dongsheng Duan
Journal:  Expert Opin Orphan Drugs       Date:  2015-12-17       Impact factor: 0.694

8.  Generation of neural cells from DM1 induced pluripotent stem cells as cellular model for the study of central nervous system neuropathogenesis.

Authors:  Guangbin Xia; Katherine E Santostefano; Marianne Goodwin; Jilin Liu; S H Subramony; Maurice S Swanson; Naohiro Terada; Tetsuo Ashizawa
Journal:  Cell Reprogram       Date:  2013-04       Impact factor: 1.987

9.  Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1.

Authors:  Ginny R Morriss; Kimal Rajapakshe; Shixia Huang; Cristian Coarfa; Thomas A Cooper
Journal:  Hum Mol Genet       Date:  2018-08-15       Impact factor: 6.150

Review 10.  RNA-protein interactions in unstable microsatellite diseases.

Authors:  Apoorva Mohan; Marianne Goodwin; Maurice S Swanson
Journal:  Brain Res       Date:  2014-04-04       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.